Nieder Carsten, Dalhaug Astrid, Pawinski Adam
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
In Vivo. 2019 Mar-Apr;33(2):465-468. doi: 10.21873/invivo.11495.
BACKGROUND/AIM: The aim of this study was to analyze the prognostic impact of biomarkers, such as serum lactate dehydrogenase (LDH), in patients with oligometastatic castration-resistant prostate cancer, arbitrarily defined as a maximum of five metastatic lesions.
This was a retrospective single-institution analysis. Overall 34 patients were included, all of whom received first-line docetaxel without ablative local treatment.
Twelve patients (35%) had elevated LDH (≥255 U/l). Their median survival was significantly shorter than that of patients with normal LDH. Due to an interaction with other biomarkers, multivariate Cox regression analysis was performed. The latter showed that serum hemoglobin was the only significant predictor of survival.
Correct diagnosis of oligometastatic disease is not trivial, because all radiological modalities are limited by certain thresholds for detection of small metastases. Serum biomarkers may reflect the total burden of malignant disease. However, this relatively small study did not clearly demonstrate that elevation of LDH may be useful for clinical decision-making, e.g. in terms of adding local treatment for all sites of metastatic spread.
背景/目的：本研究旨在分析生物标志物，如血清乳酸脱氢酶（LDH），对寡转移去势抵抗性前列腺癌患者的预后影响，寡转移定义为最多五个转移病灶。
这是一项单机构回顾性分析。共纳入34例患者，所有患者均接受一线多西他赛治疗，未进行消融性局部治疗。
12例患者（35%）LDH升高（≥255 U/l）。他们的中位生存期明显短于LDH正常的患者。由于与其他生物标志物存在相互作用，因此进行了多变量Cox回归分析。结果显示血清血红蛋白是唯一显著的生存预测指标。
寡转移疾病的正确诊断并非易事，因为所有影像学检查方法都受小转移灶检测的某些阈值限制。血清生物标志物可能反映恶性疾病的总体负担。然而，这项规模相对较小的研究并未明确表明LDH升高可能有助于临床决策，例如在对所有转移扩散部位增加局部治疗方面。
